172 related articles for article (PubMed ID: 22908172)
1. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Coilly A; Furlan V; Roche B; Barau C; Noël C; Bonhomme-Faivre L; Antonini TM; Roque-Afonso AM; Samuel D; Taburet AM; Duclos-Vallée JC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5728-34. PubMed ID: 22908172
[TBL] [Abstract][Full Text] [Related]
2. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
[TBL] [Abstract][Full Text] [Related]
3. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.
Al Nahdi N; Ford JA; Greanya ED; Harrigan JA; Tse I; Steinbrecher UP; Erb SR; Yoshida EM
Ann Hepatol; 2013; 12(1):156-60. PubMed ID: 23293209
[TBL] [Abstract][Full Text] [Related]
4. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA
PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189
[TBL] [Abstract][Full Text] [Related]
5. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
[TBL] [Abstract][Full Text] [Related]
9. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
[TBL] [Abstract][Full Text] [Related]
11. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
Duvoux C; Villamil F; Renner EL; Grazi GL; Firpi RJ; Pageaux G; Mulhaupt B; Schirm F; Rauer B; Bernhardt P; Levy G
Ann Transplant; 2015 Jan; 20():25-35. PubMed ID: 25588713
[TBL] [Abstract][Full Text] [Related]
15. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
16. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Coilly A; Dumortier J; Botta-Fridlund D; Latournerie M; Leroy V; Pageaux GP; Agostini H; Giostra E; Moreno C; Roche B; Antonini TM; Guillaud O; Lebray P; Radenne S; Saouli AC; Calmus Y; Alric L; Debette-Gratien M; De Ledinghen V; Durand F; Duvoux C; Samuel D; Duclos-Vallée JC
PLoS One; 2015; 10(9):e0138091. PubMed ID: 26394142
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
20. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]